BAYRY Quote, Financials, Valuation and Earnings

CureVac NV has a net margin of -2.86% compared to Bayer AG's net margin of 68.44%. Bayer AG's return on equity of -7.79% beat CureVac NV's return on equity of 21.3%.

Bayer AG has a consensus price target of $8.76, signalling upside risk potential of 31.73%. On the other hand CureVac NV has an analysts' consensus of $6.24 which suggests that it could grow by 78.76%. Given that CureVac NV has higher upside potential than Bayer AG, analysts believe CureVac NV is more attractive than Bayer AG.

Bayer AG has a beta of 0.839, which suggesting that the stock is 16.066% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.47%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -5.13% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Bayer AG quarterly revenues are $12.5B, which are larger than CureVac NV quarterly revenues of $543.2M. Bayer AG's net income of -$357.1M is lower than CureVac NV's net income of $371.8M. Notably, Bayer AG's price-to-earnings ratio is -- while CureVac NV's PE ratio is 4.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.52x versus 1.33x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Fresenius Medical Care AG has a net margin of -2.86% compared to Bayer AG's net margin of 3.1%. Bayer AG's return on equity of -7.79% beat Fresenius Medical Care AG's return on equity of 4.05%.

Bayer AG has a consensus price target of $8.76, signalling upside risk potential of 31.73%. On the other hand Fresenius Medical Care AG has an analysts' consensus of $26.60 which suggests that it could fall by -5.79%. Given that Bayer AG has higher upside potential than Fresenius Medical Care AG, analysts believe Bayer AG is more attractive than Fresenius Medical Care AG.

Bayer AG has a beta of 0.839, which suggesting that the stock is 16.066% less volatile than S&P 500. In comparison Fresenius Medical Care AG has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.616%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.47%. Fresenius Medical Care AG offers a yield of 2.28% to investors and pays a quarterly dividend of $0.64 per share. Bayer AG pays -5.13% of its earnings as a dividend. Fresenius Medical Care AG pays out 64.91% of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bayer AG quarterly revenues are $12.5B, which are larger than Fresenius Medical Care AG quarterly revenues of $5.1B. Bayer AG's net income of -$357.1M is lower than Fresenius Medical Care AG's net income of $159.1M. Notably, Bayer AG's price-to-earnings ratio is -- while Fresenius Medical Care AG's PE ratio is 24.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.52x versus 0.79x for Fresenius Medical Care AG. Usually stocks with elevated PS ratios are considered overvalued.

Merck KGaA has a net margin of -2.86% compared to Bayer AG's net margin of 12.31%. Bayer AG's return on equity of -7.79% beat Merck KGaA's return on equity of 9.8%.

Bayer AG has a consensus price target of $8.76, signalling upside risk potential of 31.73%. On the other hand Merck KGaA has an analysts' consensus of $37.10 which suggests that it could grow by 34.76%. Given that Merck KGaA has higher upside potential than Bayer AG, analysts believe Merck KGaA is more attractive than Bayer AG.

Bayer AG has a beta of 0.839, which suggesting that the stock is 16.066% less volatile than S&P 500. In comparison Merck KGaA has a beta of 0.992, suggesting its less volatile than the S&P 500 by 0.801%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.47%. Merck KGaA offers a yield of 1.82% to investors and pays a quarterly dividend of $0.50 per share. Bayer AG pays -5.13% of its earnings as a dividend. Merck KGaA pays out 10.23% of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bayer AG quarterly revenues are $12.5B, which are larger than Merck KGaA quarterly revenues of $5.8B. Bayer AG's net income of -$357.1M is lower than Merck KGaA's net income of $711M. Notably, Bayer AG's price-to-earnings ratio is -- while Merck KGaA's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.52x versus 2.61x for Merck KGaA. Usually stocks with elevated PS ratios are considered overvalued.

Siemens Healthineers AG has a net margin of -2.86% compared to Bayer AG's net margin of 8.65%. Bayer AG's return on equity of -7.79% beat Siemens Healthineers AG's return on equity of 10.69%.

Bayer AG has a consensus price target of $8.76, signalling upside risk potential of 31.73%. On the other hand Siemens Healthineers AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Bayer AG has higher upside potential than Siemens Healthineers AG, analysts believe Bayer AG is more attractive than Siemens Healthineers AG.

Bayer AG has a beta of 0.839, which suggesting that the stock is 16.066% less volatile than S&P 500. In comparison Siemens Healthineers AG has a beta of 1.060, suggesting its more volatile than the S&P 500 by 6.049%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.47%. Siemens Healthineers AG offers a yield of 3.81% to investors and pays a quarterly dividend of $0.50 per share. Bayer AG pays -5.13% of its earnings as a dividend. Siemens Healthineers AG pays out 54.74% of its earnings as a dividend. Siemens Healthineers AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bayer AG quarterly revenues are $12.5B, which are larger than Siemens Healthineers AG quarterly revenues of $5.8B. Bayer AG's net income of -$357.1M is lower than Siemens Healthineers AG's net income of $505.3M. Notably, Bayer AG's price-to-earnings ratio is -- while Siemens Healthineers AG's PE ratio is 27.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.52x versus 2.40x for Siemens Healthineers AG. Usually stocks with elevated PS ratios are considered overvalued.